Ireland's Tanaiste Simon Harris Urges Mutual Benefit in US-EU Trade Negotiations

Ireland's Deputy Prime Minister Simon Harris recently met with representatives from the US pharmaceutical industry to discuss the ongoing Section 232 investigation into the sector. The meeting aimed to gather insights from the industry ahead of crucial negotiations between the EU and the US. Harris emphasized the importance of avoiding an escalatory tariff outcome that would harm both sides of the Atlantic. He also highlighted the significant trade and investment partnerships in the pharmaceutical sector between Ireland and the US.

Key Takeaways:

• The Section 232 investigation is focused on national security issues, but Ireland argues that the integrated supply chain in pharma products between the EU and the US supports collective transatlantic economic security.
• Ireland's position is that the treatment of pharma should be within negotiations with the EU on an agreement in principle, which has been conveyed to both sides of the Atlantic.
• Pharmaceutical companies value Ireland's highly talented and skilled labor market, as well as access to the EU market of over 450 million people.
• Harris stressed the need for a negotiated settlement that results in mutually beneficial transatlantic trade and investment before August 1.
• The EU has shown restraint in countering tariffs, underscoring its desire for a negotiated outcome.
• The Irish government aims to achieve the best outcome for patients and citizens on both sides of the Atlantic.

Statistics:

• Over 450 million people have access to the EU market through pharmaceutical companies based in Ireland.
• The industry values its presence in Ireland due to access to a highly talented and skilled labor market.

Sources:

• "Tanaiste Simon Harris urges mutual benefit in US-EU trade negotiations" by Cate McCurry (PA)